| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
CH1055 triethylamine does not directly target a specific receptor or enzyme; its function is as a fluorescent dye for molecular imaging. It is conjugated with targeting ligands like anti-EGFR Affibody for specific tumor imaging.
|
|---|---|
| ln Vitro |
As a fluorescent dye, CH1055 triethylamine exhibits excellent photophysical properties suitable for deep-tissue imaging. It can be conjugated with antibodies or ligands for specific imaging applications, such as tumor imaging in vivo.
|
| ln Vivo |
In vivo, CH1055 triethylamine is a rapidly excreted dye, with approximately 90% excreted via the kidneys within 24 hours, allowing for high-contrast imaging. It enables targeted molecular imaging of tumors when conjugated with anti-EGFR Affibody and allows for precise image-guided tumor-removal surgery.
|
| Enzyme Assay |
Standard protocols for evaluating NIR-II fluorophores like CH1055 involve measuring their fluorescence quantum yield, absorbance spectra, and photostability. The compound is dissolved in an appropriate solvent like DMSO, and its fluorescence is measured at relevant wavelengths to confirm its suitability for imaging.
|
| Cell Assay |
In vitro cellular assays for CH1055 triethylamine are designed to assess its cellular uptake and cytotoxicity. Typically, cancer cells (e.g., HeLa or 4T1 cells) are incubated with varying concentrations of the dye for 24-72 hours. Cell viability is then measured using a standard CCK-8 assay or by flow cytometry.
|
| Animal Protocol |
For in vivo animal studies, tumor-bearing mice (e.g., nude mice with subcutaneous xenografts) are injected intravenously with CH1055 triethylamine conjugated to a targeting ligand. Fluorescence imaging is performed at multiple time points post-injection using an NIR-II imaging system. Tissue distribution and tumor-to-background ratio are calculated.
|
| ADME/Pharmacokinetics |
CH1055 triethylamine exhibits favorable pharmacokinetic properties for an imaging agent. It demonstrates rapid renal clearance, with approximately 90% of the dye being excreted through the kidneys within 24 hours post-administration. This rapid clearance reduces background signal and improves imaging contrast.
|
| Toxicity/Toxicokinetics |
As a fluorescent dye, CH1055 triethylamine is considered low in toxicity for research applications. Standard safety data for fluorescent dyes indicate that acute toxicity is low, with no significant adverse effects observed in animal models at typical imaging doses. It is categorized for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
CH1055 triethylamine is a NIR-II fluorophore that enables imaging with high signal-to-background ratio due to reduced tissue autofluorescence and scattering. Its small molecular weight (970 Da) facilitates rapid renal clearance. It has been successfully used in image-guided tumor resection surgery and is available as a research-grade chemical (≥98% purity).
|
| Molecular Formula |
C60H59N7O8S2
|
|---|---|
| Molecular Weight |
1070.28
|
| Related CAS # |
CH1055;1622250-38-7
|
| Appearance |
Green to dark green solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9343 mL | 4.6717 mL | 9.3433 mL | |
| 5 mM | 0.1869 mL | 0.9343 mL | 1.8687 mL | |
| 10 mM | 0.0934 mL | 0.4672 mL | 0.9343 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
